1. >
  2. search-en

Search

Found 417 Results
Page 2 of 42

Publication of the 2021 Annual Financial Report


Paris (France), April 28, 2022 – 6.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]

04/28/2022



Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer


Agarwal is Currently Chairwoman of Onxeo’s Board, a Position Held Since June 2021 Company Outlines Development Strategy Plans Including Preparation […]

04/07/2022


Onxeo Reports its Full-Year 2021 Financial Results and announces additional financing of €12 million


Cash position of €17.9 million as of December 31, 2021 Additional financing of €12 million subscribed by historical shareholders Invus […]

04/06/2022


Onxeo to present new preclinical data highlighting AsiDNA™’s ability to fight tumor resistance and protect from anticancer treatment toxicity at AACR Annual Meeting 2022


AsiDNA™ proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA™ proven to protect healthy cells when […]

03/31/2022


Combined General Meeting (April 19, 2020 | 2:00 pm)


Extraordinary General Meeting (April 19, 2020 | 2:00 pm)

03/24/2022


AACR Annual Meeting 2022 (April 8 – 13, 2022)


AACR Annual Meeting 2022 (April 8 – 13, 2022)


Annual General Meeting 2022


COMBINED GENERAL MEETING 2022 Combined General Meeting of 17 August 2022 07/13/2022 – Notice of meeting valid as a convocation […]

03/14/2022


Onxeo’s new preclinical data confirm the relevance of combining AsiDNA™ with PARP inhibitors in treating homologous recombination proficient tumors


These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022   Paris (France), March 9, 2022 – 7:00 […]

03/09/2022


Onxeo Announces its Financial Agenda for 2022


Paris (France), January 13, 2022 – 6 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), […]

01/13/2022


Page 2 of 42

No more results